Heart disease

#Biomedical research #Biotechnology #Drug discovery #Heart disease #mRNA-based vaccines

This week in Drug Discovery (13 – 17 July) 

News round-up for 13 – 17 July by Bruno Quinney, Content Team at DDW.  This week, a new drug has shown potential to treat heart disease. Elsewhere, Cancer Research UK is leading a global cancer trial.  The top stories:  New drug could treat common heart disease, study… Read More

#News

Heart
#Clinical trial #Drug discovery #Heart disease #The University of Manchester

New drug could treat common heart disease, study shows 

A new drug that reduces heart muscle thickening could represent a new treatment option for heart disease patients, a study says.  The TEMPEST trial, led by researchers at the University of Manchester, tested the drug trientine in 154 adults with hypertrophic cardiomyopathy in a year-long, placebo-controlled study. Read More

#News

#Bladder cancer #Covid-19 #Drug discovery #Heart disease #Lung disease #Oncology

This week in Drug Discovery (22-26 June) 

News round-up for 22–26 June by Bruno Quinney, Content Team at DDW.  This week, the Summer issue of DDW is now available to read. Elsewhere, researchers have uncovered clues explaining risks of heart disease, lung disease, Covid-19 and cancer.    The top stories: … Read More

#News

Cholesterol test
#Cholesterol #Drug development #Heart disease #University of California San Diego

Hidden pathway could be targeted to reduce heart disease 

A hidden biological pathway could be targeted to reduce cholesterol-related heart disease, research shows.  A team from the University of California San Diego School of Medicine uncovered a biological pathway involving the liver, explaining why high-cholesterol diets impede the body’s ability to clear harmful low-density lipoprotein (LDL)… Read More

#News

Heart
#AAV #Circio Holding #Gene therapy #Heart disease

Circio and AaviGen collaborate on heart disease gene therapy 

Biotechnology companies Circio Holding and AaviGen have announced a research collaboration to develop heart disease gene therapies.  The agreement will see the companies work to develop circVec-enhanced AAV vectors specifically engineered for targeted, low dose heart gene therapy.   The collaboration focus will be on addressing genetic… Read More

#News

#AI #Heart disease #Lung disease #Qureight

Qureight appoints Rebecca Simmons as COO 

Techbio company Qureight has appointed Rebecca Simmons as the company’s Chief Operating Officer.  Simmons will be responsible for scaling the company’s global business operations and leading sustainable growth initiatives. The appointment comes as Qureight aims to drive adoption and integration of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials for… Read More

#News

#AI #Heart disease #Lung disease #Qureight

Qureight appoints Dr Steven Bishop as CMO 

Techbio company Qureight has announced the appointment of Dr Steven Bishop as Chief Medical Officer.  Bishop previously served as Chief Data Officer for the company, which uses AI-powered CT imaging biomarkers and its clinical data management platform to advance understanding of lung and heart diseases.  As CMO, Bishop… Read More

#News

Knee x-ray
#Drug repurposing #Heart disease #Kyoto University

Study finds heart disease drug promotes bone growth

New research has shown that phosphodiesterase (PDE) 3 inhibitors, used for treating thrombosis, heart diseases, and asthma, can promote bone growth by stimulating C-type natriuretic peptide (CNP) signalling.  Scientists have found that PDE3 inhibitors stimulate key signalling pathways that trigger Ca2+ influx into bone cells, promoting extracellular… Read More

#News

Human heart
#Cardiovascular disease #Heart disease #Phase II trial #RNA #Silence Therapeutics

Silence Therapeutics presents late-breaking Phase II data at AHA

Biotechnology company Silence Therapeutics has shared end-of-treatment data from its Phase II ALPACAR-360 study of short interfering RNA (siRNA) zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein levels. These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific… Read More

#News

Professor Glenn King working in the lab with a funnel web spider. Credit The University of Queensland
#Clinical trial #Heart attack #Heart disease #Medical Research Future Fund #University of Queensland

Spider venom heart drug moves to human clinical trials

A project to develop a drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF). Professor Glenn King from the University of Queensland’s (UQ) Institute for Molecular Bioscience… Read More

#News

#Bone disease #Collaboration #Heart disease #mRNA #Oncology #Partnership

This week in drug discovery (20-24 May) 

News round-up for 20-24 May by DDW Senior Digital Content Editor Diana Spencer. The headline news this week emphasises the importance of shared expertise and collaboration, whether that be between nations, companies or research institutions, to enable the greatest advances in drug discovery. The top stories:… Read More

#News

Precision medicine
#Cell culture #Drug targets #Heart disease #Precision medicine

Partners explore precision medicine approach to heart disease  

PlaqueTec and the Welch research group at the Babraham Institute have announced the completion of their collaboration to evaluate lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec.  The project was funded by the UKRI-BBSRC Campus Innovation Award (CIA), via the Babraham Research Campus Collaboration… Read More

#News

Heart attack patient with doctor
#ARMGO Pharma #Cardiovascular disease #Heart disease #Phase II trial #Rare disease

Trials of new drug for rare genetic heart disease enter Phase II

ARMGO Pharma has enrolled the first patient in a Phase II proof-of-concept clinical trial using its Rycal ARM210 (also known as S48168), for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT). The trial, performed at the Amsterdam University Medical Center (Amsterdam UMC), Netherlands and the Mayo… Read More

#News

Cardiovascular system
#Cardiovascular disease #Heart disease #HIV #National Institutes of Health (NIH) #Statins

Daily statin reduces the risk of cardiovascular disease in HIV

A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin medication was found to reduce the increased risk of cardiovascular disease among people living with HIV. This was the first large-scale clinical study to test a primary cardiovascular prevention strategy in… Read More

#Editor's Choice #News

Cholesterol test
#Heart disease #Monoclonal antibodies #Phase I trial #Vaccines #Vaxxinity

LDL cholesterol vaccine ‘could be a game-changer’

The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. The drug works by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9). “We’re… Read More

#Editor's Choice #News